Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: A cross-sectional survey

Osteoporosis International

Volumn 17, Issue 11, 2006, Pages 1638-1644

  Carr, A J ^a,d   Thompson, P W ^b   Cooper, C ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d Hale House   (United Kingdom)

Author keywords

Adherence; Bisphosphonates; Compliance; Osteoporosis; Patient preference

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; ADVERTIZING; ANAMNESIS; ARTICLE; ATTITUDE TO HEALTH; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FEMALE; FRACTURE; HAZARD ASSESSMENT; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL SOCIETY; OSTEOPOROSIS; PAIN; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; POLYPHARMACY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SELF REPORT; STATISTICAL ANALYSIS; TELECOMMUNICATION; TREATMENT DURATION; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CROSS-SECTIONAL STUDIES; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; PATIENT SATISFACTION; RISK FACTORS;

EID: 33749186614     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-006-0166-2     Document Type: Article

References (18)

1. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 15:1003-1008
2. Tosteson AN, Grove MR, Hammond CS et al (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209-216
3. Miller NH (1997) Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102:43-49
4. Simon JA, Lewiecki EM, Smith ME et al (2002) Patient preference for once-weekly aledronate 70 mg versus once daily aledronate 10 mg: a multicenter, randomised, open label, crossover study. Clin Ther 24:1871-1886
5. Donovan JL, Blake DR (1992) Patient noncompliance: deviance or reasoned decision-making? Soc Sci Med 34:507-513
6. Donovan JL, Blake DR, Fleming WG (1989) The patient is not a blank sheet: lay beliefs and their relevance to patient education. Br J Rheumatol 28:58-61
7. Horne R (1999) Patients' beliefs about treatment: the hidden determinant of treatment outcome? J Psychosom Res 47:491-495
8. Carr AJ, Hughes RA, Vincent K, Carr M, Thwaites C (2004) The impact and implications of new treatments in arthritis: validation of a questionnaire to measure the 'real life' effectiveness of medication. Rheumatology 43(suppl):ii83
9. O'Neill TW, Cooper C, Cannata JB, Diaz Lopez, Hoszowski K et al (1994) Reproducibility of a questionnaire on risk factors for osteoporosis in a multicentre prevalence survey: The European Vertebral Osteoporosis Study. Int J Epidemiology 23(3):559-565
10. Fletcher RH (1989) Patient compliance with therapeutic advice: a modern view. The Mount Sinai Journal of Medicine 56:453-458
11. Kaplan RM, Simon HJ (1990) Compliance in medical care: reconsideration of self-predictions. Annals of Behavioural Medicine 12:66-71
12. Turbí C, Herrero-Beaumont G, Acebes JC, Torrijos A, Graña J, Miguélez R, Sacristán JA, Marín F (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 26:245-256
13. Cramer J, Amonkar M, Hebborn A, Suppapanya N (2004) Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women? J Bone Miner Res 19(Suppl 1):S448 (Abstract M434)
14. Unson CG, Siccion E, Gaztambide J, Gaztambide S, Mahoney Trella P, Prestwood K (2003) Nonadherence and osteoporosis treatment preferences of older women: a qualitative study. J Women's Health 12:1037-1045
15. Kendler D, Kung AWC, El-Hajj Fuleihan G, González JGG, Gaines KA, Verbruggen N, Melton ME (2004) Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48; 243-251
16. Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871-1886
17. Boccuzzi SJ, Folz SH, Omar MA, Kahler KH (2005) Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporosis Int 16(Suppl 4):S35-S36 (Abstract P7.10)
18. Ettinger MP, Gallagher R, Amonkar M, Smith JC, MacCosbe PE (2004) Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum 15(Suppl.):S513 (Abstract 1325)